Loading ......
REGN5093-M114 is a bispecific antibody-drug conjugate engineered to engage MET, the hepatocyte growth factor receptor, on malignant cells through dual epitope recognition while ferrying a dolaflexin-derived cytotoxic payload for intracellular release. By concentrating the antimitotic effector within MET-overexpressing tumor tissue, the construct seeks to widen the therapeutic margin relative to non-selective cytotoxic chemotherapy. This sophistication, however, generates an unusually layered bioanalytical landscape: the intact conjugate, the antibody component alone, the released payload, shed receptor-mediated target sink, and treatment-emergent anti-drug antibodies all coexist in patient circulation. Meaningful interpretation of pharmacokinetic and safety data therefore requires immunoassay reagents capable of resolving each molecular species independently and in combination.
Figure 1. REGN5093-M114 (ADC) ELISA Kit: Comprehensive Immunoanalytical Toolkit for MET-Directed Bispecific Antibody-Drug Conjugate Exposure and Payload Characterization.
Antibody-drug conjugate development imposes analytical obligations that extend well beyond ordinary monoclonal antibody pharmacokinetics. The intact conjugate carrying its payload is the pharmacologically decisive species, yet linker chemistry permits gradual payload exchange or release, generating analyte populations with distinct safety implications. Target-mediated disposition through receptor binding and internalization further distorts simple exposure expectations, particularly in tumors expressing abundant MET antigen. Concurrent measurement of soluble MET pathway components, receptor occupancy, and anti-drug antibody incidence contextualizes these phenomena. A defensible bioanalytical strategy therefore layers ligand-specific immunoassays for the intact conjugate, receptor-focused quantification, and payload-focused detection into one interpretive framework, enabling program teams to connect dose, target burden, conjugate integrity, and immunogenicity within a single coherent dataset.
| Analytical / Molecular Targets | Descriptions |
| MET Receptor (HGFR) | Transmembrane receptor tyrosine kinase activated by hepatocyte growth factor; overexpressed or dysregulated across solid tumors and exploited as the dual-engagement target of the REGN5093 bispecific scaffold. |
| Intact Conjugated Antibody Component | Complete antibody-drug conjugate species retaining both MET-binding arms and the attached dolaflexin-derived payload; the pharmacologically relevant molecular form quantified by the REGN5093-M114 (ADC) ELISA Kit. |
| M114 Payload Species | Cytotoxic auristatin-family effector released intracellularly following lysosomal catabolism of internalized conjugate; responsible for microtubule-directed tumor cell killing and monitored as a molecular entity distinct from the antibody component. |
Upon intravenous infusion, REGN5093-M114 navigates systemic circulation and binds MET receptors on tumor cell surfaces through its bispecific recognition arms. Receptor-mediated internalization routes the conjugate into lysosomal compartments where catabolic processing liberates the cytotoxic effector, while a residual fraction of circulating conjugate undergoes proteolytic clearance independent of target engagement. The relative dominance of target-mediated versus non-specific clearance shifts with tumor antigen burden, shaping observed exposure and demanding analyte-specific interpretation. As with other protein therapeutics, treatment-emergent anti-drug antibodies may arise during repeated administration. Such antibodies can accelerate conjugate clearance through immune complex formation, neutralize receptor-binding competence, or alter payload release kinetics, each scenario carrying distinct efficacy and safety ramifications. Soluble MET shed from tumor surfaces introduces yet another interpretive variable, functioning as a circulating sink that binds conjugate and diminishes the fraction available for tumor engagement. Deploying the REGN5093-M114 (ADC) ELISA Kit in concert with MET receptor quantification, hepatocyte growth factor measurement, and orthogonal ADC reference assays enables laboratories to profile intact conjugate exposure, target pathway dynamics, payload-related species, and immunogenic signals simultaneously, equipping development teams with the layered evidence demanded by oncology regulatory review.
| Products | Core Advantages | Primary Applicable Scenarios |
| REGN5093-M114 (ADC) ELISA Kit | Ligand-binding assay architecture selective for the intact MET-directed conjugate; distinguishes payload-carrying species from unconjugated antibody; dependable performance across human serum matrices | Intact conjugate pharmacokinetic profiling; exposure-response correlation in oncology trials; comparative assessment across dose escalation designs |
| Human MET proto-oncogene, receptor tyrosine kinase ELISA Kit | Quantitative sandwich measurement of soluble and shed MET receptor in patient biofluids; contextualizes target-mediated clearance; compatible with serum and plasma workflows | Target burden estimation prior to and during therapy; interpretation of receptor-mediated drug sink phenomena; patient stratification research |
| Human HGF(Hepatocyte Growth Factor) ELISA Kit | Sensitive quantification of the natural MET ligand; illuminates competitive pathway dynamics that influence conjugate engagement; consistent performance across human specimen types | Ligand-receptor axis characterization alongside conjugate monitoring; pathway biomarker correlation studies; tumor microenvironment research |
| Hi-Puri™ Human Anti-Human MET Monoclonal antibody | High-purity anti-MET monoclonal reagent suited to assay development and specificity confirmation; stable manufacturing consistency; adaptable to capture or detection configurations | Custom bioanalytical assay construction; method transfer reference material; orthogonal confirmation of MET-directed assay selectivity |
| Humanized Anti-Human cMet-MMAE ADC [Telisotuzumab vedotin] | Reference ADC reagent pairing a cMet-directed antibody with an auristatin payload; serves as method development comparator for conjugate-specific immunoassays; supports cross-program analytical benchmarking | Assay interference and cross-reactivity testing; ADC platform method development; comparative bioanalysis within the MET-targeted class |
Bispecific antibody-drug conjugate programs concentrate complex analytical demands within oncology laboratories, contract research organizations, and translational research units. The assay portfolio described here delivers the layered measurement capability such programs require, spanning candidate qualification through pivotal trial support.
Bioanalytical interrogation of a bispecific MET-directed antibody-drug conjugate demands analytical resolution across molecular species that ordinary immunoassay panels cannot provide. The coordinated portfolio anchored by the REGN5093-M114 (ADC) ELISA Kit, reinforced by MET receptor and hepatocyte growth factor quantification, high-purity anti-MET antibody reagents, and orthologous ADC comparators, supplies orthogonal measurements that together reconstruct conjugate fate from infusion through payload release. Every assay is engineered with optimized capture-detection pairings, validated across human serum matrices, and built to generate reproducible, traceable quantitative data appropriate for regulatory dossiers and laboratory reporting. Deployed as a unified panel, these platforms link intact conjugate exposure, target pathway dynamics, payload-related analytes, and immunogenicity signals into one mechanistic narrative. For oncology bioanalytical laboratories and biopharmaceutical developers, this assay ecosystem delivers the standardized analytical foundation required to advance MET-targeted conjugate programs from candidate selection through pivotal evaluation with confidence and regulatory readiness.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25396 | REGN5093-M114 (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA7180 | Human MET proto-oncogene, receptor tyrosine kinase ELISA Kit | 96T | Human | Quantitative | sandwich ELISA | Inquiry |
| DEIA727 | Human HGF(Hepatocyte Growth Factor) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......